Novo Nordisk

News

11 blockbuster drugs to look out for in 2025

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

News

Novo Nordisk asks FDA not to allow GLP-1 compounding

Novo Nordisk has asked the FDA to block compounders from making versions of its older, once-daily GLP-1 agonist liraglutide.

News

FDA approves flurry of drugs ahead of holiday season

The FDA has wrapped up a series of new approvals as 2024 draws to a close, with Novo Nordisk, Pfizer, Vertex, and Hikma among the beneficiaries.

News

Novo Nordisk sheds billions in value on obesity data

Novo Nordisk data on obesity candidate CagriSema falls short of expectations, wiping around $94 billion off its market valuation.

News

Novo completes $16.5bn takeover of Catalent

Novo Holdings' $16.5bn takeover of US CDMO Catalent has been completed, after months of debate over potential antitrust issues.

News

Representation of Odense production facility and warehouse

Novo sets aside $1.2bn for rare diseases plant

Novo Nordisk has started building its first brand-new manufacturing facility in Denmark this century and will spend around $1.2bn on the plant.

11 blockbuster drugs to look out for in 2025

Novo Nordisk asks FDA not to allow GLP-1 compounding

FDA approves flurry of drugs ahead of holiday season

Novo Nordisk sheds billions in value on obesity data

Novo completes $16.5bn takeover of Catalent

Novo sets aside $1.2bn for rare diseases plant

Consolidating data strategy for global success: Insights fro...

How to meet your physicians where they are online

Novo Nordisk

Editor's Picks